Cm Management, LLC Neu Base Therapeutics, Inc. Transaction History

Cm Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$0.17 - $0.39 $39,100 - $89,700	-230,000 Reduced 65.71%	120,000 $22,000
Q4 2022 Feb 09, 2023	SELL	$0.18 - $0.3 $18,000 - $30,000	-100,000 Reduced 22.22%	350,000 $67,000
Q3 2022 Nov 04, 2022	BUY	$0.41 - $1.3 $32,800 - $104,000	80,000 Added 21.62%	450,000 $178,000
Q2 2022 Aug 08, 2022	BUY	$0.82 - $1.93 $36,900 - $86,850	45,000 Added 13.85%	370,000 $389,000
Q1 2022 May 09, 2022	BUY	$1.26 - $2.95 $220,500 - $516,250	175,000 Added 116.67%	325,000 $611,000
Q4 2021 Feb 02, 2022	BUY	$2.6 - $4.18 $195,000 - $313,500	75,000 Added 100.0%	150,000 $422,000
Q3 2021 Nov 08, 2021	BUY	$3.27 - $4.76 $245,250 - $357,000	75,000 New	75,000 $271,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cm Management, LLC with notifications on news.